Associated tags: Health, Baxter International, NYSE, Medical Devices, Medical Supplies, Hospitals, Biotechnology, Baxter, Surgery, Health Technology, Patient, Pharmaceutical, General Health
Locations: UNITED STATES, NORTH AMERICA, ILLINOIS, EUROPE, AFRICA, NEW YORK, GEORGIA, CONNECTICUT, MASSACHUSETTS, WARBURG, US, AUSTRALIA, SPAIN, SAUDI ARABIA, PHILADELPHIA, EGYPT, COLOMBIA, IV, GUATEMALA, CHICAGO, NEW ZEALAND, IRELAND, UNITED KINGDOM, UK, RAYMOND, IQ
Health,
Hospitals,
Health Technology,
Other Health,
Managed Care,
General Health,
Baxter,
Baxter International,
In re Caremark International Inc. Derivative Litigation,
ICU,
Multimedia,
Patient,
NYSE,
Management,
Pharmaceutical industry Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses.
- Until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by July 2024 or earlier, Mr. Toth will serve as executive vice president and group president, Kidney Care, and report to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective June 1, 2023.
- View the full release here: https://www.businesswire.com/news/home/20230505005086/en/
Chris Toth, selected to be chief executive officer (CEO) of Baxter's planned spinoff of its Renal Care and Acute Therapies businesses.
- “Baxter’s Kidney Care enterprise is a leader in the global industry, serving more than one million patients annually as a trusted partner to providers and clinicians around the world,” said Mr. Toth.
Medical Supplies,
Medical Devices,
Health,
General Health,
Pharmaceutical,
Biotechnology,
Baxter International,
Moran v. Household International, Inc.,
NYSE,
Holding company Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
- The dividend is payable on July 3, 2023, to shareholders of record as of June 2, 2023.
- The indicated annual dividend rate is $1.16 per share of common stock.
Biotechnology,
Managed Care,
Medical Supplies,
Surgery,
Health,
Medical Devices,
Hospitals,
Fitness & Nutrition,
Galaxy,
DNA,
ALF,
Agility,
Noise,
Piperacillin,
Fort Robinson breakout,
Pump,
Baxter,
COVID-19,
Thrombin,
IQ,
GAAP,
Baxter International,
U.S. FDA,
Tazobactam,
Acute liver failure,
Information International, Inc.,
Hospital,
Patient,
Generally Accepted Accounting Principles (United States),
Injection,
Novum,
Liver,
Growth,
CDT,
SYR,
NYSE,
LVP,
Cryptocurrency,
Fine chemical,
Pharmaceutical industry,
Management,
Security (finance) Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
- On an adjusted basis, net income attributable to Baxter totaled $297 million, or $0.59 per diluted share, a 37% decrease.
- Baxter expects to report quarterly performance in line with the new operating model beginning in the second half of 2023.
- Among recent corporate responsibility highlights, Baxter and the Baxter International Foundation advanced support for disaster relief in response to February’s devastating earthquake in Turkey and Syria.
Retrieved on:
Wednesday, April 19, 2023
Medical Supplies,
Finance,
Hospitals,
Banking,
Professional Services,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Baxter International,
SRI International, Inc. v. Internet Security Systems, Inc.,
Bank of America,
BofA Securities,
Medtech,
Conference,
NYSE,
Risk management Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023.
- Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
- The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through November 5, 2023.
Biotechnology,
Medical Supplies,
Surgery,
General Health,
Health,
Medical Devices,
Hospitals,
Health Technology,
Central Time,
Webcast,
Baxter International,
SRI International, Inc. v. Internet Security Systems, Inc.,
Medtech,
NYSE,
Cryptocurrency,
Music,
Video game Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time.
- To participate in this conference call please follow this link https://conferencingportals.com/event/WhpPxesO to pre-register for the call and receive the call information.
- This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
- The conference call will be recorded by Baxter and is copyrighted material.
Medical Supplies,
Health,
Hospitals,
Other Health,
Managed Care,
Pharmaceutical,
Biotechnology,
Baxter,
Piperacillin,
Baxter International,
Tazobactam,
Information International, Inc.,
Galaxy,
Patient,
NYSE,
Patient safety,
Injection,
Pharmaceutical industry,
Medication Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.
Key Points:
- Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.
- “Zosyn premix is an important addition to Baxter’s portfolio of valuable anti-infective medications that help treat some of the most pressing healthcare needs facing patients today,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter.
- Baxter will sell Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100mL presentations.
- Like other medications in Baxter’s premix portfolio, Zosyn premix uses Baxter’s proprietary Galaxy container technology.
Surgery,
Medical Devices,
Hospitals,
Health,
Medical Supplies,
DNA,
Association of periOperative Registered Nurses,
OR,
Thrombin,
PST,
Baxter International,
Information International, Inc.,
Thermoregulation,
Perioperative,
Hemostasis,
AORN,
Patient,
Bleeding,
Conference,
NYSE,
Nursing,
Medical device Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.
Key Points:
- Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.
- The system is also air-free, which may reduce risks associated with forced air systems1—such as contamination of the surgical site—and operates quietly.
- The Baxter Patient Warming system is compatible with its TS7000, TS7000dV and PST 500 surgical tables.
- Baxter also revealed a first look at its Helux Pro Connected Surgical Light, a wired lighting and camera solution for the operating room.
Retrieved on:
Wednesday, March 29, 2023
Surgery,
Medical Devices,
Medical Supplies,
Hospitals,
Fitness & Nutrition,
Biotechnology,
Other Health,
Managed Care,
Health,
Online,
Central Time,
Baxter,
Baxter International,
Ouellette v. Viacom International Inc.,
Medtech,
NYSE,
Annual general meeting,
Holding company,
Online shopping,
Shareholder Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2023 Annual Meeting) in a virtual format on Tuesday, May 2, 2023 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the meeting.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2023 Annual Meeting) in a virtual format on Tuesday, May 2, 2023 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the meeting.
- If you plan to attend the virtual meeting, please check https://investor.baxter.com for updates prior to the meeting date.
- As always, whether or not you plan to attend the virtual 2023 Annual Meeting, you are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials for the meeting.
- A list of Baxter's stockholders of record will be available for examination by stockholders on the meeting website during the meeting.
Retrieved on:
Tuesday, February 14, 2023
Surgery,
Medical Devices,
Medical Supplies,
Hospitals,
Fitness & Nutrition,
Biotechnology,
Other Health,
Managed Care,
Health,
Moran v. Household International, Inc.,
NYSE,
Baxter International,
Holding company Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
- The dividend is payable on April 3, 2023, to shareholders of record as of February 24, 2023.
- The indicated annual dividend rate is $1.16 per share of common stock.
Retrieved on:
Thursday, February 9, 2023
Surgery,
Medical Devices,
Medical Supplies,
Hospitals,
Fitness & Nutrition,
Biotechnology,
Other Health,
Managed Care,
Health,
ACT,
Organization,
Baxter,
CST,
UN,
In re Caremark International Inc. Derivative Litigation,
Fort Robinson breakout,
Patient,
United Nations Sustainable Development Group,
Corporation,
NYSE,
Acquisition,
Historically black colleges and universities,
GAAP,
Peritoneal dialysis,
100 Best Companies to Work For,
Sale,
Research,
Cardiology,
Minister of Employment, Workforce Development and Disability Inclusion,
BVLOS drone medical delivery trials in India,
Black,
Baxter International,
Growth,
P&L,
Responsibility,
Generally Accepted Accounting Principles (United States),
Community,
Dow Jones,
Commitment,
BPS,
GBU-53/B StormBreaker,
COVID-19,
R,
GBU,
Video game,
Management,
Fine chemical,
Pharmaceutical industry,
Cryptocurrency,
Nursing,
Insurance,
Hill-Rom,
University Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023.
- For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.
- “In 2022, Baxter returned approximately $600 million to shareholders through dividends and share repurchases.
- Was cited among top scoring companies on Disability:IN’s 2022 Disability Equality Index, designating Baxter as a Best Place to Work for Disability Inclusion.
